LATISSE®

LATISSE® solution, a prescription treatment for hypotrichosis, promotes the growth of eyelashes, making them longer, thicker and darker. Hypotrichosis is another name for having inadequate or not enough eyelashes.

LATISSE® is believed to affect the growth (anagen) phase of the eyelash hair cycle in two ways: first, it increases the length of this phase; and second, it increases the number of hairs in this growth phase. The exact way it works is unknown.

Skin hyperpigmention (or skin darkening) is a less common side effect, which typically occurs close to where the solution is applied on the skin. This is due to an increase of melanin in the skin. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible in most patients upon discontinuation of bimatoprost. Skin hyperpigmention (or skin darkening) is a less common side effect, which typically occurs close to where the solution is applied on the skin. This is due to an increase of melanin in the skin. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible in most patients upon discontinuation of bimatoprost.

Increased brown iris pigmentation has occurred when the same formulation of bimatoprost ophthalmic solution was instilled directly into the eye to treat elevated intraocular pressure. Although iris pigmentation was not reported in clinical studies with LATISSE®, patients should be advised about the potential for increased brown iris pigmentation which is likely permanent.

Throughout clinical trials, some users did experience itchy eyes and eye redness. However, some users found that these irritations went away once they became accustomed to the product or began applying it properly. Skin hyperpigmention (or skin darkening) is a less common side effect, which typically occurs close to where the solution is applied on the skin. This is due to an increase of melanin in the skin. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible in most patients upon discontinuation of bimatoprost. Increased brown iris pigmentation has occurred when the same formulation of bimatoprost ophthalmic solution was instilled directly into the eye to treat elevated intraocular pressure. Although iris pigmentation was not reported in clinical studies with LATISSE®, patients should be advised about the potential for increased brown iris pigmentation which is likely permanent.

To maintain effect, continued treatment with LATISSE® is required. If use of LATISSE® is discontinued, eyelashes will gradually return to where they were prior to treatment over a period of weeks to months (average eyelash hair cycle).

LATISSE® users can expect to experience longer, fuller and darker eyelashes in as little as eight weeks, with full results in 16 weeks.